Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: J Am Acad Child Adolesc Psychiatry. 2020 Oct 20;60(7):877–886. doi: 10.1016/j.jaac.2020.09.023

Table 1.

Annual Prescription Antipsychotic Use in Privately Insured Young Children (2–7 Years), 2007–2017

Year Persons with antipsychotic prescription Antipsychotic usea,b Antipsychotic use standardized by divisionc
Total Boys Girls
2007 3,778 0.27% 0.26% 0.40% 0.12%
2008 7,368 0.29% 0.29% 0.44% 0.13%
2009 8,035 0.29% 0.29% 0.44% 0.13%
2010 6,960 0.27% 0.27% 0.41% 0.12%
2011 7,182 0.26% 0.26% 0.39% 0.12%
2012 7,067 0.26% 0.26% 0.39% 0.12%
2013 4,981 0.23% 0.24% 0.37% 0.11%
2014 4,322 0.20% 0.21% 0.31% 0.10%
2015 2,964 0.18% 0.19% 0.28% 0.09%
2016 2,771 0.17% 0.17% 0.26% 0.08%
2017 2,501 0.17% 0.16% 0.25% 0.08%

Note:

a

Denominator: Count of children aged 2–7 years enrolled in a covered insurance plan with prescription drug coverage in July of that year

b

Antipsychotic prevalence was highest in 2009. Prevalence overall, and stratified in boys and girls, was not statistically significantly higher in 2009 than in 2008; antipsychotic prevalence in 2009 was significantly (p<0.01) higher than in 2010. The linear trend of antipsychotic use from 2009 to 2017 declined by 0.017% (95% CI: −0.018 to −0.016, p<0.01) per year.

c

Antipsychotic use estimates standardized by geographical division (reference year = 2011, unknown division excluded); categories included: New England, Middle Atlantic, South Atlantic, East North Central, East South Central, West North Central, West South Central, Mountain, or Pacific